title: Necrolytic migratory erythema in a patient with neuroendocrine carcinoma.
abstract: Necrolytic migratory erythema is an obligatory paraneoplastic syndrome. Here we describe a patient with a neuroendocrine tumor of probably pancreatic origin. She developed the typical skin lesions under chemotherapy with temozolomide and capecitabine.
authors.affiliation: National Center for Tumor Diseases Heidelberg, Germany. michaela.gronau@med.uni-heidelberg.de
authors.forename: Michaela
authors.initials: M
authors.lastname: Gronau
authors.forename: Dirk
authors.initials: D
authors.lastname: Jäger
authors.forename: Alexander H
authors.initials: AH
authors.lastname: Enk
authors.forename: Jessica C
authors.initials: JC
authors.lastname: Hassel
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols; D001707:Biopsy, Needle; D000069287:Capecitabine; D018278:Carcinoma, Neuroendocrine / Q000175:diagnosis* / Q000188:drug therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003841:Deoxycytidine / Q000031:analogs & derivatives / Q000627:therapeutic use; D003937:Diagnosis, Differential; D003875:Drug Eruptions / Q000175:diagnosis* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D058568:Necrolytic Migratory Erythema / Q000175:diagnosis* / Q000473:pathology; D009367:Neoplasm Staging; D010190:Pancreatic Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D010257:Paraneoplastic Syndromes / Q000175:diagnosis* / Q000473:pathology; D018570:Risk Assessment; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D003841:Deoxycytidine; D000069287:Capecitabine; D003606:Dacarbazine; D005472:Fluorouracil; D000077204:Temozolomide